Dyax Corp. (NASDAQ: DYAX) announced today, based on successful antibody discovery work during a research evaluation period, Bayer Pharma AG (Bayer) has executed a license to Dyax’s antibody phage display technology for development and potential commercialization of therapeutic antibody candidates identified using the Dyax library.
“In an increasingly crowded antibody discovery technology space, we are pleased to provide Bayer with our proven technology for their antibody discovery efforts,” said Gustav Christensen. “With the first program from our evaluation period already moving ahead to the next research milestone, we look forward to continuing support of Bayer’s efforts to maintain and enhance its world-class biologics pipeline.”
By providing its partners with state-of-the art libraries and technology, Dyax has enabled its licensees to bring 18 programs into active clinical development—four of those programs are currently in Phase III and four are in Phase II.
About Dyax’s Phage DisplayDyax’s phage display technology has powered therapeutic and diagnostic candidate discovery across a wide range of therapeutic areas. For more than 15 years, Dyax has developed and improved the tools that enable the effective and rapid screening of its proprietary, state-of-the-art, antibody or peptide libraries, each containing billions of members to identify candidate molecules fitting exacting and challenging sets of lead candidate criteria. As an originator of phage display technology and with consistent leadership in the field, Dyax possesses both the deep technical expertise as well as state-of-the-art tools to assist its partners in minimizing risk and maximizing speed in reaching the clinic with their candidate molecules. Partners can access Dyax’s fully-human antibody and peptide libraries through the Dyax Licensing and Funded Research Program. About Dyax Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s lead product, ecallantide, has been approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.